She called the panel “useless” and asked her functional medicine doctor: what does food sensitivity testing actually tell you, and should she trust it?
The food sensitivity testing industry is worth billions of dollars annually and generates more confusion per dollar spent than perhaps any other category of diagnostic testing in medicine. Not because the concept of immune reactivity to foods is wrong — immune reactivity to food antigens is real, documented, and clinically significant in ways standard allergy testing misses.
It’s because the tests being sold, the mechanisms they measure, and the clinical significance of their findings are poorly understood by the practitioners ordering them, the companies selling them, and the patients taking out credit cards to pay for them.
This cuts through the noise. It explains the actual immunology of food reactions — there are multiple distinct mechanisms, and conflating them is the source of most confusion. It evaluates the specific tests available — IgG, IgA, IgE, mediator release testing, cytokine assays — against the evidence for what they actually detect and whether that detection is clinically meaningful. And it provides a framework for when food sensitivity testing provides genuine clinical value and when it doesn’t.
The Immunology of Food Reactions: Four Distinct Mechanisms
The term “food sensitivity” gets used colloquially to mean almost anything — food allergy, food intolerance, food-related digestive distress, food preferences avoided for no particular reason. For clinical purposes, food reactions involving the immune system fall into four distinct categories defined by the Gell-Coombs classification of hypersensitivity reactions, and confusing them leads to incorrect testing and misguided treatment.
Type I hypersensitivity is the classic food allergy mediated by IgE antibodies. When a sensitized individual encounters an allergen (peanut, tree nuts, shellfish, fish, milk, egg, wheat, sesame — the “Big Nine” in US food labeling), IgE antibodies bound to mast cells and basophils cross-link, triggering immediate histamine and other mediator release. The symptoms are rapid-onset (minutes to two hours): hives, angioedema, wheezing, anaphylaxis. This is what standard allergy testing (skin prick test, ImmunoCAP IgE) measures.
Well-validated, clinically meaningful, and appropriate for the symptoms it’s designed to detect.
Type III hypersensitivity involves IgG (and sometimes IgA) antibodies that form immune complexes with food antigens. These complexes can deposit in tissues and activate complement, triggering inflammation. This is the proposed mechanism for IgG food reactions — the basis of most commercial food sensitivity panels.
The controversy here is significant: IgG antibodies to food antigens are ubiquitous in healthy individuals, they’re markers of normal immune exposure to food (the immune system makes antibodies to what it encounters), and the presence of IgG antibodies doesn’t reliably predict clinical symptoms. More on this below.
Type IV hypersensitivity (delayed hypersensitivity) is T-cell mediated and doesn’t involve antibodies. The prototypical example is celiac disease, in which gluten peptides activate T-cells in the intestinal mucosa, driving enterocyte destruction. Type IV reactions develop over days rather than hours, which explains why celiac disease and related conditions are so difficult to diagnose clinically without testing — the connection between eating wheat and feeling terrible two days later isn’t obvious.
Standard food allergy testing doesn’t detect Type IV reactions.
Non-immunological food intolerance is the fourth category and arguably accounts for most cases of what patients call “food sensitivities.” Lactose intolerance (lactase enzyme deficiency), fructose malabsorption (impaired GLUT5 transporter), histamine intolerance (diamine oxidase insufficiency), FODMAP sensitivity (fermentable carbohydrate malabsorption and gas production), and salicylate sensitivity (non-immunological prostaglandin pathway effects) are all genuine, clinically documented food reactions that don’t involve the immune system and won’t be detected by any immunological test.
Treating these as immune-mediated problems and ordering antibody panels leads to misdiagnosis and inappropriate treatment.
IgG Food Testing: The Controversy Examined
IgG-based food sensitivity testing is the most commercially successful and most scientifically controversial category of food reaction testing. The tests measure IgG4 (in most panels) or total IgG (in some) antibodies to panels of food antigens ranging from 20 to 200 or more foods. The marketing claims that elevated IgG antibodies indicate foods causing delayed inflammatory reactions, which should be eliminated from the diet. The mainstream immunological and allergology community has consistently rejected this interpretation.
The core scientific objection is straightforward: IgG antibodies to foods are a normal consequence of oral tolerance. When the immune system encounters food antigens — as it does with every meal — it generates IgG antibodies as part of a normal, regulatory immune response that tolerates rather than attacks food proteins.
Well-controlled studies have found that individuals who eat more of a food tend to have higher IgG antibodies to that food — the opposite of what a pathological sensitivity model would predict. Breastfed infants have IgG antibodies to foods their mothers eat. Immunotherapy for food allergies works partly by increasing food-specific IgG4, not decreasing it.
The evidence for clinical benefit from IgG-guided dietary elimination is mixed and methodologically weak. The most cited positive study is a 2004 trial published in Gut by Atkinson and colleagues, which found that eliminating IgG-positive foods in IBS patients produced greater symptom improvement than sham elimination at twelve weeks (10 percent reduction in symptoms compared to 26 percent in the true elimination group).
This finding has been used extensively to market IgG testing, but the study has significant limitations: IBS symptoms fluctuate substantially, the “sham” group was still told to eliminate foods (creating expectation effects), and the symptom reduction magnitude — while statistically significant — was modest and consistent with placebo effect in a highly placebo-responsive condition.
The counterargument from the functional medicine community is that the absence of strong clinical trial evidence doesn’t mean the tests are clinically useless — it means they haven’t been adequately studied in the right populations with the right outcomes.
There’s a plausible mechanism by which elevated IgG to specific foods could be clinically significant in specific contexts: when intestinal permeability is elevated, dietary antigens cross into submucosa in larger quantities than normal, potentially generating IgG responses to foods that wouldn’t normally trigger significant immune activation.
In this scenario, elevated food IgG may be more a marker of intestinal permeability than a direct cause of symptoms — and the appropriate intervention is repairing the permeability rather than eliminating the foods.
The position of most immunologists — including the European Academy of Allergy and Clinical Immunology (EAACI), which has issued a position paper against IgG food testing — is that IgG testing shouldn’t be used for diagnosing food allergy or guiding dietary elimination because the evidence base is insufficient and the risk of unnecessary dietary restriction is significant.
The functional medicine community continues to use these tests, often with reported clinical benefit that may reflect placebo effect, the benefits of any significant dietary change, or the indirect benefit of eliminating highly processed or inflammatory foods that happen to test positive.
IgA Food Antibodies: The Mucosal Layer
IgA-based food testing occupies a different position than IgG testing because secretory IgA is the primary immunoglobulin of the mucosal immune system and has established roles in intestinal immune defense. Mucosal IgA antibodies to specific food antigens — particularly gliadin — carry documented clinical significance.
Anti-gliadin IgA (AGA) is the original serological test for celiac disease, and while it’s been largely replaced by the more specific anti-tissue transglutaminase IgA (anti-tTG IgA) and anti-endomysial IgA (EMA) tests for celiac diagnosis, AGA remains clinically relevant for non-celiac gluten sensitivity (NCGS). Patients with NCGS may have elevated AGA without the celiac-specific antibodies (anti-tTG and EMA), indicating mucosal immune reactivity to gliadin without the autoimmune intestinal destruction of celiac disease.
A key development in gluten-related testing is the work of Aristo Vojdani and others on the sensitivity of testing multiple gluten fractions rather than just alpha-gliadin. Wheat contains not only multiple gliadin fractions (alpha, beta, gamma, omega) but also glutenins, wheat germ agglutinin, and other potentially immunogenic proteins. Testing for reactivity to multiple wheat components increases sensitivity for gluten-related disorders and has been used to identify patients with negative standard celiac panels who still have measurable wheat-related immune reactivity.
Cyrex Laboratories’ Array 3 is the most comprehensive commercial panel of this type and has been used in research on gluten-related neurological disorders.
Secretory IgA testing in stool (as discussed in the GI-MAP article) provides complementary information to serum IgA food testing. Stool sIgA reflects the mucosal immune system’s capacity to defend against antigens in the gut lumen — low sIgA may paradoxically be associated with higher systemic food antigen exposure (because the mucosal barrier isn’t blocking antigen penetration) even without elevated serum antibodies.
Mediator Release Testing (MRT): A Different Approach
The hypothesis: cells that release more inflammatory mediators when challenged with a specific food antigen indicate that the patient’s immune system responds to that food with inflammatory activation, regardless of which specific antibody-mediated or non-antibody-mediated mechanism is involved.
The clinical rationale for MRT is that it attempts to capture the functional end result of immune activation — mediator release — rather than measuring a single upstream component (IgG antibodies) that may or may not be connected to the inflammatory response. Because it measures cell behavior rather than antibody levels, it theoretically captures both antibody-mediated and non-antibody-mediated immune activations simultaneously.
The clinical evidence for MRT is somewhat stronger than for IgG testing. A 2008 pilot study found that MRT-guided dietary elimination produced significant improvement in IBS symptoms at four weeks. A 2013 study found benefit for migraine using MRT-guided elimination. The methodology has been criticized for poor reproducibility — different blood samples from the same patient on different days can give different results — and for the complexity of the testing protocol, which makes independent replication difficult.
The LEAP (Lifestyle, Eating, And Performance) protocol, developed by dietitian Jimmy Scott, combines MRT results with a structured reintroduction approach and has clinical adherents, though large, well-controlled trials are still lacking.
Celiac Disease Testing: The High-Validity Reference Point
Celiac disease testing represents the gold standard of food sensitivity testing — well-validated, mechanistically understood, clinically actionable, and supported by strong evidence. Examining what makes celiac testing reliable helps clarify why other food sensitivity panels are less so.
The validated celiac panel includes: anti-tissue transglutaminase IgA (anti-tTG IgA), which has 95 percent sensitivity and 95 percent specificity for celiac disease when total IgA is normal; anti-endomysial IgA (EMA), with similar performance; and deamidated gliadin peptide (DGP) antibodies for patients with IgA deficiency (roughly 2 to 3 percent of the population), for whom IgA-based tests give false negatives.
Total IgA must always be measured alongside these tests — IgA deficiency causes false negative results for all IgA-based celiac tests.
Confirmatory duodenal biopsy showing villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes remains the gold standard for celiac diagnosis, though the 2020 European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines allow biopsy-free diagnosis in children with very high anti-tTG (above 10 times upper limit of normal) and positive EMA plus genetic testing (HLA-DQ2/DQ8).
HLA-DQ2 and HLA-DQ8 genetic testing is valuable for ruling out celiac disease — roughly 97 percent of celiac patients carry HLA-DQ2 or DQ8 (or both), meaning the absence of both essentially excludes celiac disease regardless of antibody results. However, 25 to 35 percent of the general population also carries these variants without developing celiac disease, so their presence doesn’t confirm diagnosis.
Non-celiac gluten sensitivity (NCGS) remains a diagnosis of exclusion — it requires ruling out celiac disease (negative serology on a gluten-containing diet), negative duodenal biopsy, and demonstration of symptom improvement with gluten elimination and return on gluten reintroduction. There’s no validated biomarker for NCGS beyond clinical response to elimination and challenge, though elevated AGA, elevated zonulin, and other findings may support the diagnosis in the right context.
FODMAP Testing and Non-Immune Food Reactions
A large proportion of people who believe they have “food sensitivities” based on digestive symptoms are actually experiencing non-immune food intolerances, particularly FODMAP-related fermentation symptoms. This distinction matters clinically because FODMAPs aren’t detected by any immunological test, and attempts to use IgG panels to identify the trigger foods will produce inaccurate results.
FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) are short-chain carbohydrates poorly absorbed in the small intestine and rapidly fermented by colonic bacteria, producing gas and osmotic effects that cause bloating, abdominal pain, flatulence, and altered stool consistency. The symptoms are identical to those practitioners and patients attribute to “food sensitivity” — but the mechanism is entirely mechanical and microbiological, not immunological.
The low-FODMAP diet has Level I evidence (multiple randomized controlled trials and meta-analyses) for symptom improvement in IBS — the highest evidence grade of any dietary intervention in gastroenterology. Roughly 70 to 75 percent of IBS patients experience significant symptom improvement with a properly implemented low-FODMAP diet. This contrasts with the weak and contested evidence for IgG-guided elimination diets in IBS.
Hydrogen and methane breath testing for fructose malabsorption, lactose malabsorption, and SIBO can objectively identify specific FODMAP-related intolerances rather than empirically eliminating all high-FODMAP foods. A positive fructose breath test indicates impaired fructose absorption — the patient can target fructose specifically rather than eliminating all FODMAPs. This more targeted approach is supported by evidence showing that prolonged restrictive elimination of all FODMAPs negatively impacts gut microbiome diversity, reducing beneficial species including Bifidobacterium and F. prausnitzii.
The Elimination-Challenge Protocol: The Most Reliable Food Sensitivity Test
The standard elimination phase removes the most common food triggers for at least three to six weeks: gluten, dairy, eggs, soy, corn, legumes, tree nuts, peanuts, and alcohol (the “Big Eight” plus common sensitivities). After at least three weeks without symptoms — or at least until the current symptom level represents clear improvement from baseline — individual foods get reintroduced one at a time, with three to five days between reintroductions to allow sufficient time for delayed reactions to manifest.
Reactions during reintroduction get noted, that food gets eliminated again, and the process continues.
The limitations of elimination-challenge protocols are practical rather than scientific. They require weeks of strict dietary compliance — difficult for many patients given the food environment, social context, and life demands. They require systematic symptom tracking. They can be confounded by natural symptom fluctuation in conditions like IBS.
And they only identify foods causing sufficiently severe or consistent reactions to be detected through the reintroduction process — subtle reactions that only occur with cumulative load may not turn up through single-food challenges.
Rachel’s solution, ultimately, wasn’t a more comprehensive panel — it was an elimination protocol guided by the categories most likely to be clinically relevant given her specific symptoms (gluten and dairy for the skin and brain fog; FODMAPs for the bloating), combined with a gut healing protocol addressing the intestinal permeability likely amplifying her reactions to multiple foods. At six months, she was eating forty-plus foods.
The six-food diet had been a trauma response, not a treatment.
When Food Sensitivity Testing Is Genuinely Useful
Having spent considerable time on the limitations and controversies of food sensitivity testing, it’s worth being clear about where it provides genuine value: specific clinical contexts with appropriate tests for the mechanism being investigated.
Celiac disease panel (anti-tTG IgA, total IgA, EMA) is genuinely useful and validated for suspected celiac disease — any patient with IBS-like symptoms, especially if associated with iron deficiency anemia, peripheral neuropathy, dermatitis herpetiformis, unexplained infertility, or family history of celiac should be tested before any dietary change.
IgE-mediated allergy testing is genuinely useful for evaluating true food allergy — history of immediate reactions to foods, eczema in children, suspected food triggers for asthma or chronic urticaria. Skin prick testing or specific IgE (ImmunoCAP) for the suspected allergens is appropriate and well-validated.
Anti-gliadin antibodies (AGA IgA and IgG) as part of a broader gluten sensitivity evaluation — including ruling out celiac — can support clinical decision-making about gluten elimination in patients with neurological symptoms, autoimmune conditions, or persistent GI symptoms negative for celiac. Cyrex Array 3 provides more comprehensive gluten reactivity data than standard panels for patients with negative celiac serology but strong clinical suspicion of gluten sensitivity.
GI-MAP anti-gliadin IgA as part of comprehensive stool testing reflects mucosal immune reactivity and is a useful component of the integrated functional GI evaluation described in the GI-MAP article. Breath testing for specific FODMAP intolerances (fructose, lactose) provides objective data for targeted dietary modification. These are the food-related tests with the strongest evidence-to-benefit ratios for clinical practice.
Immunology Food Reactions: Your Questions Answered
My IgG food panel showed 30+ reactive foods — should I eliminate all of them?
No. As explained above, widespread IgG reactivity to many foods is a common finding that often reflects intestinal permeability (leaky gut) allowing more food antigens into systemic circulation, or simply reflects frequently eaten foods (which naturally generate higher IgG). Eliminating thirty foods creates nutritional risk, significant psychological stress around eating, and social impairment — none of which support recovery.
A more rational approach is identifying the pattern: are there specific categories of high-reactivity foods (gluten, dairy, eggs are common) that also correlate with your symptoms? Use the panel as one data point, not an absolute mandate. Combine it with an elimination-challenge protocol for the highest-scoring foods and with gut-healing interventions that address the intestinal permeability that may be driving the widespread reactivity.
What is the difference between a food allergy, food intolerance, and food sensitivity?
Food allergy technically refers to IgE-mediated Type I hypersensitivity — the immediate, potentially life-threatening reactions associated with peanuts, shellfish, and similar triggers. Food intolerance refers to non-immune reactions — lactose intolerance, fructose malabsorption, histamine intolerance — where the digestive or enzymatic processing of a food is impaired. Food sensitivity is a non-technical term used variably to mean non-IgE immune reactions (IgG, IgA, T-cell mediated), food intolerances, or any negative food reaction that isn’t a classic IgE allergy.
The clinical importance of distinguishing these is that different mechanisms require different testing and different interventions — treating a histamine intolerance as an IgG food sensitivity leads to useless IgG testing and incorrect elimination rather than addressing DAO enzyme support and low-histamine dietary modification.
Can I do food sensitivity testing if I have already eliminated suspect foods?
For IgG testing: ideally the tested foods should be eaten for six to eight weeks before testing, since IgG antibodies diminish rapidly after food elimination — within weeks, IgG to an eliminated food falls to low or negative, creating a false negative.
For celiac testing: critically important — celiac antibodies normalize on a gluten-free diet, so testing must occur while eating gluten regularly (at least two servings of gluten daily for six to eight weeks is the standard recommendation). Testing for celiac on an already gluten-free diet isn’t clinically valid and frequently produces false negatives that give patients false reassurance that they don’t have celiac.
If gluten has already been eliminated, a gluten challenge (six to eight weeks of regular gluten consumption before testing) or genetic HLA typing (which doesn’t require gluten challenge) are alternatives.
Is there a reliable test for histamine intolerance?
Histamine intolerance results from impaired histamine degradation, primarily through deficiency of the enzyme diamine oxidase (DAO). A serum DAO enzyme activity test is available and can confirm DAO deficiency, though the test hasn’t been extensively validated in large populations and the threshold for clinical significance isn’t universally agreed upon. Plasma histamine levels can be elevated but are difficult to measure reliably due to histamine instability in blood samples.
The most practically useful diagnostic approach remains clinical: symptoms consistent with histamine excess (flush, headache, nasal congestion, hives, gut symptoms occurring after histamine-rich foods — aged cheese, wine, fermented foods, histamine-liberating foods) improving on a low-histamine diet is strong clinical evidence regardless of laboratory testing. DAO supplementation (taken before high-histamine meals) can serve as a therapeutic trial that’s also diagnostically informative.
How do I find a practitioner who can appropriately interpret food sensitivity testing?
Look for practitioners who can articulate the specific mechanism being tested (IgE vs. IgG vs. T-cell mediated vs. non-immune), acknowledge the limitations of the specific test they’re recommending, use the test results as one component of clinical assessment rather than the sole determinant of treatment, and have a plan beyond elimination — a gut healing protocol, a reintroduction strategy, or a treatment for the underlying mechanism.
Be cautious of practitioners who recommend comprehensive IgG panels without discussing their limitations, who recommend eliminating every reactive food indefinitely, or who use food sensitivity testing as the primary diagnostic and therapeutic tool without addressing underlying gut health. The best practitioners in this space understand that food reactions are often a downstream consequence of intestinal permeability and microbiome disruption, and they address the cause rather than endlessly restricting the diet.
The Leaky Gut Connection: Why Food Reactions Multiply Over Time
The intestinal epithelium is a single cell layer separating the contents of the gut lumen — food antigens, bacteria, toxins, metabolic products — from the lamina propria, where the mucosal immune system resides. Tight junctions between epithelial cells are the molecular gates controlling what passes through.
When tight junctions are disrupted — through inflammation, dysbiosis, gluten (which stimulates zonulin release even in non-celiac individuals), NSAIDs, alcohol, psychological stress, or infection — dietary antigens that would normally be excluded from immune contact get allowed through in larger quantities than normal.
The immune system is designed to be tolerant of food antigens arriving through normal oral exposure. But when food antigens arrive via a breached barrier — particularly if the lamina propria is already in an inflammatory state — the immune response shifts from tolerogenic to reactive. The mucosal immune system generates antibodies and activates T-cells against the newly encountered antigens. If barrier disruption persists, this process continues with additional food antigens, progressively expanding the reactivity profile.
This mechanism explains several clinical observations: why food reactions often multiply after a triggering event (infection, intensive antibiotic course, significant stress); why fixing the gut barrier — rather than continuing to eliminate more foods — eventually reduces the number of apparent reactions; and why patients on extremely restricted diets sometimes develop new reactions to their remaining safe foods (because continued barrier disruption exposes the immune system to even those foods in a reactive context).
The therapeutic implication is clear: the primary intervention for multiple food sensitivities is not progressive dietary elimination but barrier repair. That means identifying and removing the drivers of intestinal permeability (gluten for susceptible individuals, ongoing dysbiosis, gut pathogens, NSAIDs, excessive alcohol, chronic stress), implementing gut-healing nutrients (L-glutamine, zinc carnosine, butyrate, colostrum), restoring microbiome balance that supports tight junction integrity (Lactobacillus species produce tight junction-supporting proteins, Akkermansia muciniphila maintains the mucus layer), and reducing systemic inflammation contributing to barrier dysfunction.
Once barrier integrity is restored, many apparent food reactions resolve spontaneously — not because the immune reactivity was imaginary, but because the mechanism generating it (barrier-breached antigen exposure in an inflammatory milieu) has been removed. Foods that previously caused reactions can often be reintroduced successfully after a gut healing period — impossible if the underlying reactions were truly fixed immune sensitizations rather than consequences of ongoing barrier dysfunction.
Mast Cell Activation and Food Reactions
Mast cell activation syndrome (MCAS) deserves specific consideration in the food sensitivity context because it creates a clinical picture that mimics multiple food sensitivities but requires a fundamentally different diagnostic and therapeutic approach. MCAS is a condition in which mast cells — tissue-resident immune cells that release histamine and dozens of other mediators when activated — are chronically hyperactivated, releasing their contents in response to triggers that wouldn’t activate mast cells in healthy individuals.
Food is one of the most common MCAS triggers. But the pattern of food reactions in MCAS is distinctive: reactions are inconsistent (the same food may cause a reaction on one day but not another), reactions often involve multiple systems simultaneously (skin, gut, cardiovascular, neurological), and reactions can be triggered by foods not high in histamine or recognized as allergenic.
The mast cell reactivity is non-specific — it reflects mast cell hyperreactivity rather than specific sensitization to particular food antigens.
Testing for MCAS includes serum tryptase (elevated in mastocytosis but often normal in MCAS), 24-hour urine prostaglandin D2 and N-methylhistamine (more sensitive for MCAS than serum tryptase), and increasingly, serum chromogranin A and heparin. The diagnosis is clinical in many cases: characteristic multisystem symptoms, improvement with mast cell stabilizers and/or antihistamine treatment, and exclusion of other conditions. Food sensitivity panels aren’t useful for MCAS diagnosis — the reactions aren’t mediated by food-specific antibodies.
MCAS management for food-related symptoms focuses on mast cell stabilization (quercetin, cromolyn sodium, ketotifen, luteolin), H1 and H2 antihistamines for symptomatic control, and identifying and reducing other mast cell triggers (stress, heat, specific medications, infections) rather than endless dietary restriction based on unreliable testing.
Understanding MCAS prevents the pattern of progressive dietary elimination that characterizes undertreated MCAS, where patients continue eliminating foods in a futile attempt to identify the “cause” of reactions actually driven by mast cell hyperreactivity rather than any specific food antigen.
Practical Testing Recommendations by Symptom Pattern
Rather than recommending specific tests universally, the most clinically useful approach is matching tests to symptom patterns. Different symptom constellations suggest different underlying mechanisms, which in turn suggest different testing priorities.
For primarily gastrointestinal symptoms (bloating, altered bowel habits, abdominal pain, nausea) — particularly if symptoms are worse after eating and better during extended fasting: prioritize celiac serology (anti-tTG IgA, total IgA) if any gluten-related symptoms; breath testing for fructose, lactose, and hydrogen/methane SIBO; GI-MAP for comprehensive gut evaluation. IgG food panel may be ordered as a secondary investigation if celiac is ruled out and symptoms persist, but shouldn’t be the first-line test.
For neurological symptoms (brain fog, headaches, peripheral neuropathy, mood changes) potentially related to diet: celiac panel is essential — gluten ataxia and gluten neuropathy are real conditions with established evidence, and neurological manifestations of celiac disease can occur without GI symptoms in up to 30 percent of cases. Anti-gliadin antibodies (including extended wheat protein panel) may be informative for non-celiac gluten sensitivity with neurological features. Anti-ganglioside antibodies should be considered for peripheral neuropathy.
Organic acids testing for quinolinic acid and kynurenine pathway assessment if brain fog is prominent.
For skin symptoms (eczema, urticaria, psoriasis, rashes): IgE-based allergy testing for immediate food allergy; celiac panel if dermatitis herpetiformis is suspected (blistering, symmetrical rash on extensor surfaces); anti-tTG IgA specifically for dermatitis herpetiformis, which is often diagnosed by skin biopsy showing IgA deposition. A low-histamine diet trial and DAO testing for urticaria patients without identifiable IgE allergens. Serum tryptase and mast cell mediators if the urticaria pattern suggests systemic mast cell disease.
For autoimmune conditions and systemic inflammatory disease: anti-tTG IgA for celiac, which is up to eight times more common in patients with other autoimmune conditions than in the general population. The gluten-autoimmunity connection is mechanistically grounded — gluten-induced intestinal permeability with subsequent immune activation may trigger autoimmune processes in genetically susceptible individuals, and resolution of celiac disease on a gluten-free diet has been associated with improvement in concurrent autoimmune conditions including thyroid disease.
Food sensitivity testing in the context of autoimmune disease should be evaluated alongside testing for intestinal permeability (zonulin) and gut dysbiosis as a comprehensive assessment of gut-immune axis dysfunction.
The net assessment on food sensitivity testing is this: the tests are tools, and their value depends entirely on asking the right questions with the right tools for the right mechanism. Used appropriately, they provide actionable information that changes treatment and improves outcomes. Used indiscriminately — ordering a 200-food IgG panel for every patient with digestive symptoms — they generate noise that obscures the signal, drives unnecessary dietary restriction, and delays effective treatment.
The practitioner who understands the immunology and can match test to mechanism is worth more to patients than any test panel.
The Practical Framework: Applying Immunology Food Reactions Four In Real Life
FROM THE LIBRARY ›
References
Editorial StandardsCorrectionsMedical DisclaimerAbout Our ContentAffiliate DisclosureSite Map